Tesamorelin: GHRH Analogue in Growth Hormone Research
What is Tesamorelin?
Tesamorelin is a GHRH analogue — a lab-made copy of the natural signal (called GHRH) that tells the body to release growth hormone. It is a peptide (a short chain of amino acids, the building blocks of proteins). It fits a lock called the GHRH receptor on the pituitary (a small gland at the base of the brain). Researchers study it as a tool for nudging the body to release its own growth hormone in natural bursts. It is supplied strictly as a research reagent for in vitro (test-tube / lab work only) use, not for human or veterinary use.
Chemically, Tesamorelin is the full natural GHRH chain (44 amino acids long) with one extra piece added to one end (called a trans-3-hexenoyl group). That small change is what makes it useful. Normal GHRH gets chopped up within minutes by enzymes in the body. The added cap acts like armour on the weak end of the peptide, so Tesamorelin lasts much longer than plain GHRH in research.
Tesamorelin works one step before growth hormone. Instead of being growth hormone itself, it tells the pituitary to make and release its own. Researchers use it to study that earlier step — how the pituitary responds to the GHRH signal — which is what makes it different from simply giving growth hormone directly. These are research observations only, not therapeutic effects.
GHRH-receptor signalling vs direct GH
The way Tesamorelin works follows a clear chain: it fits its receptor, that sets off a signal inside the cell, the pituitary releases growth hormone in bursts, and that growth hormone then triggers a second signal called IGF-1. The effects on metabolism (how the body uses energy and handles fat) are the most studied part.
Receptor binding and the cAMP cascade
Tesamorelin fits the GHRH receptor on cells in the pituitary called somatotrophs (the cells that make growth hormone). When the receptor switches on, it raises a tiny “messenger” molecule inside the cell called cAMP. That rise in cAMP makes the cell both build and release growth hormone. Because it works through the cell’s own machinery, researchers use Tesamorelin to test how well these cells respond and whether the GHRH signalling is working properly.
Pulsatile release vs direct growth hormone
The key point is that Tesamorelin works one step earlier. It asks the pituitary to release the body’s own growth hormone in its natural rhythm of bursts, keeping the body’s normal feedback controls in place. Giving growth hormone directly skips the pituitary completely and gives a flat, steady level instead of natural bursts. For researchers studying how the growth-hormone system is controlled, keeping those natural bursts is exactly what makes a GHRH analogue a truer tool than plain growth hormone.
Downstream GH and the IGF-1 axis
The growth hormone that Tesamorelin helps release then acts on the body’s tissues and triggers IGF-1 (insulin-like growth factor 1), the messenger behind many of growth hormone’s effects. So research with Tesamorelin reaches past the pituitary to the wider growth-hormone/IGF-1 system and how it affects metabolism.
Metabolic research context
The most studied result of GHRH-analogue signalling is on metabolism — especially effects on visceral fat (the fat stored deep around the organs) and how the body handles fats. This is the area Tesamorelin has been studied most. In research settings it is used as a tool to look at how prompting the body’s own growth hormone changes where fat sits and other metabolic markers. These are research observations only, not therapeutic effects.
Key research findings
Tesamorelin research mixes lab and animal work with some controlled human studies. The studies below are summarised here for science reference only. A few use human data, included just to help explain how it works.
Characterised the pharmacology of the GHRH analogue now known as Tesamorelin (TH9507), establishing the non-clinical profile that underpins its use as a GH-axis research tool.
A controlled study reporting that the GHRH analogue stimulated endogenous GH/IGF-1 signalling and was associated with reduced visceral adipose tissue — included here for mechanistic context, as human clinical data rather than preclinical research.
Tesamorelin and CJC-1295
Tesamorelin is often studied next to CJC-1295, another GHRH analogue (lab-made copy of the GHRH signal). Both fit the same GHRH receptor, but they are built a bit differently and last in the body for different lengths of time. That gives researchers two related but separate tools to compare. Both belong to the somatotropic research category. For a side-by-side look, see CJC-1295 vs Tesamorelin.
Velox Peptides supply information
Velox Peptides supplies Tesamorelin as a lyophilised (freeze-dried) powder at ≥99% HPLC-verified purity, with a batch certificate of analysis (a lab report proving what is in the vial) available on request. To work out how to reconstitute it (mix the powder back into a liquid), see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.
References & further reading
- Ferdinandi ES et al. “Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.” Basic & Clinical Pharmacology & Toxicology, 2007.
- Falutz J et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” New England Journal of Medicine, 2007. (Human clinical data — included for mechanistic context only.)
Summaries are paraphrased from the peer-reviewed preclinical literature. For full source citations, email veloxpeps@gmail.com.
